New hope for advanced breast cancer: drug combo trial launches
NCT ID NCT07163481
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tests a drug called sacituzumab govitecan combined with hormone therapy in 12 people with HR-positive, HER2-negative metastatic breast cancer that has worsened after CDK4/6 inhibitor treatment. The main goal is to check safety and side effects, while also looking at how well the tumors shrink. It is a small, first-in-human combination study, so results are preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sacituzumab govitecan (a drug that targets cancer cells) combined with endocrine therapy (fulvestrant, anastrozole, or exemestane)
What this could lead to
If successful, this could point toward a new combination treatment option for people with advanced breast cancer that has stopped responding to standard therapies.
What could go wrong
This is a very early, small Phase Ib trial with only 12 participants, focused mainly on safety. The combination may not prove effective or could cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV (METASTATIC) BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hunan Cancer Hospital
Changsha, Hunan, 410000, China